Literature DB >> 1119966

Occipital lobe arteriovenous malformations. Clinical and radiologic features in 26 cases with comments on differentiation from migraine.

B T Troost, T H Newton.   

Abstract

The differentiation of migraine headache, preceded by visual aura, from cerebral arteriovenous malformation (AVM) is often regarded as difficult. A study of 26 patients with occipital lobe AVM revealed two distinct syndromes in 18 patients--occipital epilepsy and occipital apoplexy. Occipital epilepsy is characterized either by elementary visual phenomena, such as brief flashes of light, or by dimming of a homonymous field. Occipital apoplexy results from hemorrhage and hematoma formation within the occipital lobe and is characterized by sudden headache and homonymous visual field loss. We conclude that patients harboring occipital AVMs may, indeed, have visual phenomena and headache that should not be confused with migraine because either a history of generalized seizure or bruits on examination will probably be present.

Entities:  

Mesh:

Year:  1975        PMID: 1119966     DOI: 10.1001/archopht.1975.01010020260002

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  5 in total

Review 1.  Diagnosis and treatment of arteriovenous malformations.

Authors:  J P Mohr; J Kejda-Scharler; J Pile-Spellman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-02       Impact factor: 5.081

2.  Symptomatic headaches.

Authors:  G Bono; P Merlo; G Sances; F Tancioni; M Mauri
Journal:  Ital J Neurol Sci       Date:  1995-12

3.  Grooves on the occipital lobe of Indian brains.

Authors:  K K Bisaria
Journal:  J Anat       Date:  1984-10       Impact factor: 2.610

4.  Elementary visual hallucinations in migraine and epilepsy.

Authors:  C P Panayiotopoulos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

5.  Computed tomography evaluation of patients with chronic headache.

Authors:  M D Dumas; J H Pexman; J H Kreeft
Journal:  CMAJ       Date:  1994-11-15       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.